kzr-261
·Code: KZR-261
kzr-261: sourced relationships with 1 company · 1 clinical trial tracked.
kzr-261 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect kzr-261 to KZR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could kzr-261 → KZR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Advanced/Metastatic Solid Tumor
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Kezar Life Sciences, Inc. (KZR) Advanced/Metastatic Solid Tumor | Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies
Primary endpoint: Number and Percentage of Participants Experiencing Adverse Events as Assessed by CTCAE v5.0 (Part 1 & 2)
Interventionalopen61 targetStarted 2021-09Completion 2025-0112 sites · United StatesKezar Life Sciences, Inc.
Frequently asked questions
Which companies have sourced relationships with kzr-261?
kzr-261 has dated SEC/FDA relationship records for Kezar Life Sciences, Inc..
How many clinical trials involve kzr-261?
BioSniper tracks 1 clinical trial involving kzr-261.